Pulse Biosciences

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but were in-line with EPS expectations. Revenue of $0.43M fell short of the $0.53M mean estimate, while GAAP EPS of -$0.36 matched consensus. The company demonstrated significant clinical momentum, surpassing the halfway point for the NANOPULSE-AF study and accelerating the enrollment timeline to early Q4. A strengthened cash position of $101.6M via ATM programs provides a stable runway for regulatory submissions through 2027.